II. Indications
-
Percutaneous Coronary Intervention (PCI) for coronary revascularization and stent placement
- Patients who have not received P2Y12 Inhibitor or Glycoprotein IIB/IIIA Inhibitor
III. Mechanism
IV. Dosing
- Load 30 mcg/kg IV before Percutaneous Coronary Intervention (PCI)
- Infuse 4 mcg/kg/min for at least 2 hours and until the procedure is complete
- Infuse via a dedicated line
- Give oral P2Y12 Inhibitor (Clopidogrel, Prasugrel, Ticagrelor) immediately after infusion complete
- Ticagrelor may be given during infusion (but NOT Clopidogrel or Prasugrel)
V. Adverse Effects
- See Platelet ADP Receptor Antagonist (P2Y12 Receptor Antagonist)
- Autoimmune-induced Dyspnea
VI. Safety
- Pregnancy Category C
- Unknown safety in Lactation
VII. Resources
Images: Related links to external sites (from Bing)
Related Studies
Concepts | Pharmacologic Substance (T121) , Nucleic Acid, Nucleoside, or Nucleotide (T114) |
MSH | C117446 |
English | Cangrelor, CANGRELOR, N(6)-(2-methylthioethyl)-2-(3,3,3-trifluoropropylthio)-5'-adenylic acid monoanhydride with dichloromethylenebis(phosphonic acid), cangrelor |